NCT07826325 Effect of Emergency Urinary Drainage on Subsequent PCNL Outcomes in Obstructive Urosepsis
| NCT ID | NCT07826325 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beni-Suef University |
| Condition | Urosepsis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-10 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-10 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Obstructive urolithiasis complicated by urosepsis is a life-threatening medical emergency requiring urgent urinary tract decompression. Emergency drainage is typically achieved by either retrograde ureteral stent (RUS) insertion or percutaneous nephrostomy (PCN). Following clinical stabilization and resolution of infection, percutaneous nephrolithotomy (PCNL) is commonly performed as definitive stone treatment. This prospective comparative study aims to evaluate and compare the outcomes of subsequent PCNL between patients who underwent emergency drainage via retrograde ureteral stent and those who underwent percutaneous nephrostomy. The main outcomes to be compared include stone-free rates, operative time, blood loss, postoperative complications, length of hospital stay, and the need for auxiliary procedures.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Presence of renal or proximal ureteral stones. * Presentation with urosepsis secondary to obstructive urolithiasis. * Emergency urinary decompression performed by either retrograde ureteral stent (Double-J stent) or percutaneous nephrostomy (PCN). * Patients scheduled for definitive stone management via percutaneous nephrolithotomy (PCNL) after clinical stabilization and infection resolution. * Written informed consent obtained prior to enrollment. Exclusion Criteria: * Congenital renal anomalies (e.g., horseshoe kidney, ectopic kidney). * Pregnancy. * Uncorrectable coagulopathy or bleeding disorders. * Active, uncontrolled urinary tract infection at the time of definitive PCNL. * Severe cardiopulmonary comorbidities rendering the patient unfit for surgery or general anesthesia. * Patients managed definitively by other modalities (e.g., ureteroscopy or ESWL alone).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07826325 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urosepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07826325 currently recruiting?
Yes, NCT07826325 is actively recruiting participants. Contact the research team at mahmoud.abdalla@med.bsu.edu.eg for enrollment information.
Where is the NCT07826325 trial being conducted?
This trial is being conducted at Banī Suwayf, Egypt.
Who is sponsoring the NCT07826325 clinical trial?
NCT07826325 is sponsored by Beni-Suef University. The trial plans to enroll 100 participants.